119th Congress · introduced in the House · Jul 2, 2025
Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Official title from Congress.gov
Latest action (Jul 3, 2025): Motion to reconsider laid on the table Agreed to without objection.
View on Congress.govPolicy area: Congress
No official summary has been published for this bill.
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
House · Jul 3, 2025 · Roll call 189 · Passed
House · Jul 2, 2025 · Roll call 188 · Agreed to · Amendment vote
House · Jul 2, 2025 · Roll call 187 · Passed
House · Jul 2, 2025 · Roll call 186 · Passed
Motion to reconsider laid on the table Agreed to without objection.
On agreeing to the resolution, as amended Agreed to by the Yeas and Nays: 219 - 213 (Roll no. 189). Roll call details
Passed/agreed to in House: On agreeing to the resolution, as amended Agreed to by the Yeas and Nays: 219 - 213 (Roll no. 189). Roll call details
DEBATE - The House proceeded with one hour of debate on H. Res. 566.
On consideration of the resolution Agreed to by the Yeas and Nays: 212 - 211 (Roll no. 186). Roll call details
Mr. McGovern moved On consideration of the resolution.
POINT OF ORDER - Mr. McGovern raised a point of order against the provisions of H. Res. 566 on the grounds that the resolution violates section 426(a) of the Congressional Budget Act. The Chair announced that the disposition of the point of order would be resolved by the question of consideration of H. Res. 566. The House proceeded with 20 minutes of debate on the point of order at the end of which the Chair will put the question on consideration.
Considered as privileged matter. (consideration: CR H3039-3059; text: CR H3040)
By direction of the Committee on Rules, Ms. Foxx called up H.Res. 566 and asked for its immediate consideration.
Placed on the House Calendar, Calendar No. 35.
The resolution makes in order a motion that the House concur in the Senate amendment to H.R. 1 and provides for one hour of debate.
The House Committee on Rules reported an original measure, H. Rept. 119-179, by Ms. Foxx.
The House Committee on Rules reported an original measure, H. Rept. 119-179, by Ms. Foxx.
Actions from Congress.gov, newest first.
House of Representatives · Legislative rules and procedure
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
11 citations.
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Budget/Appropriations
$7,360,000
Spent on own lobbying
…nd Related Agencies Appropriations Act, 2027 S.___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 16, 2026 · issue area: Budget/Appropriations
$890,000
Spent on own lobbying
…d Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 21, 2026 · issue area: Budget/Appropriations
$1,640,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Budget/Appropriations
$12,210,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Budget/Appropriations
$8,410,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 21, 2025 · issue area: Budget/Appropriations
$1,700,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN · lobbying firm or registrant: THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Budget/Appropriations
$70,000
Spent on own lobbying
…ovisions pertaining to health program funding H.R.1 - One Big Beautiful Bill Act; a bill to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.Res.566 - Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14.FY26 Labor, HH…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Budget/Appropriations
$9,030,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GSK (FKA GLAXOSMITHKLINE INC.) · lobbying firm or registrant: GSK (FKA GLAXOSMITHKLINE INC.)
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Budget/Appropriations
$1,510,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN · lobbying firm or registrant: THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Budget/Appropriations
$240,000
Spent on own lobbying
…ovisions pertaining to health program funding H.R.1 - One Big Beautiful Bill Act; a bill to provide for reconciliation pursuant to title II of H. Con. Res. 14. H.Res.566 - Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14.FY26 Labor, HH…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Budget/Appropriations
$7,580,000
Spent on own lobbying
…elated Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Depa…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing